New York, NYNCT06090227Now EnrollingIRB Ready

Focal Segmental Glomerulosclerosis Clinical Trial in New York, NY

Access cutting-edge focal segmental glomerulosclerosis treatment through this phase 1/2 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Yale University

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access focal segmental glomerulosclerosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related focal segmental glomerulosclerosis treatment provided free

Apply for This New York Location

Check if you qualify for this focal segmental glomerulosclerosis clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Focal Segmental Glomerulosclerosis Study in New York

The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged greater than or equal to 18 years, but \</= 80 years age at the time of signing the informed consent
Biopsy-confirmed primary FSGS as defined by expert renal pathology at either institutions. For homogeneity of diagnoses, demonstrable segmental or global sclerosis lesions (\>/=1 glomerulus) with diffuse podocyte foot process effacement by electron microscopy (\>/+ 50% of examined glomerular tufts), or show evidence of mesangial expansion or mesangial sclerosis, also confirmed by electron microscopy.
Therapeutic plan by treating physician for immunomodulatory treatment using Glucocorticoids.
Ability to take oral medication and be willing to adhere to the MF or Placebo regimen
For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of VPA administration. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion Criteria

Liver disease: confirmed cirrhosis liver (any stage), acute hepatitis (\> 2 fold increase in liver enzymes, any coagulopathy, hyperbilirubinemia, ascites or encephalopathy)
estimated GFR \< 32 ml/min
Diabetes Mellitus diagnosis at the time of biopsy or need for oral hypoglycemic agents/Insulin, or taking Metformin for other indications
Treatment with another investigational drug or other intervention within 3 months
Current pregnancy or desire to become pregnant during the study period
Unwilling to use two forms of birth control (for women of childbearing age)
Under hospice care
Confirmed Dementia diagnoses in EMR problem list
Incarceration
Homelessness
Inability to consent
Currently enrolled in (or completed within the past 30 days) a study of an investigational drug or device.
Life expectancy of less than 6 months as determined by the clinical judgement of the patient's primary physician
Allergy or sensitivity to Metformin
Platelet count \< 100,000/µL; INR \> 1.5; Bleeding diathesis or blood thinner use contraindicating biopsy.
Bleeding diathesis or blood thinner use contraindicating biopsy will be excluded entirely from participation in research biopsy portion of study only, even if anticoagulation/blood thinners can be held temporarily.
Simultaneous use of Carbonic anhydrase inhibitor agents
Use of systemic immunosuppressive medication for non-renal indications

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT06090227) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Focal Segmental Glomerulosclerosis Treatment Options in New York, NY

If you're searching for focal segmental glomerulosclerosis treatment options in New York, NY, this clinical trial (NCT06090227) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced focal segmental glomerulosclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all focal segmental glomerulosclerosis clinical trials near you to find additional studies recruiting in your area.

More Nephrotic Syndrome Trials in New York, NY

See all nephrotic syndrome clinical trials recruiting in New York — not just this study.

Browse Nephrotic Syndrome Trials in New York →

Browse More Trials by Condition

Nephrotic Syndrome TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY